• Read more about Predicting Response to BET Inhibitors Using a Computational Model and it's Validation: A Beat AML Project Study

Background: Despite advances in our understanding of the molecular pathogenesis of acute myeloid leukemia (AML), the prognosis remains poor, mainly due to high relapse rates. Therefore, novel treatment strategies are needed to improve therapeutic outcomes for AML patients.

• Read more about Predicting Response to IDH1/IDH2 Inhibitors Beyond IDH Mutations Using a Computational Model and it's Validation: A Beat AML Project Study

Background: Isocitrate dehydrogenase (IDH) is an essential enzyme in the TCA cycle. Recurrent mutations in IDH1 or IDH2 are prevalent in several cancers, including glioma and acute myeloid leukemia (AML). IDH mutations reduce cellular levels of α-ketoglutarate (α-KG), resulting in accumulation of 2-hydroxyglutarate (2-HG), an α-KG antagonist. 

• Read more about Digital Drug Screening and Computational Modeling Identifies Treatment Opportunities Despite Lack of Directly Actionable Mutations in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Background: Although virtually all patients (pts) with AML or MDS harbor at least one somatic mutation, a minority of pts possess genetic mutations considered directly targetable by a drug. Moreover, in pts with multiple gene mutations, single-gene/single-drug matching often produces conflicting drug recommendations.

• Read more about A Genomic Signature Predicting Venetoclax Treatment Response in Acute Myeloid Leukemia (AML) Identified By Protein Network Mapping and Validated By Ex Vivo Drug Sensitivity Testing

• Read more about Icare 1: A Prospective Clinical Trial to Predict Treatment Response Based on Mutanome-Informed Computational Biology in Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

• Read more about iCare 1: A prospective clinical trial to predict treatment response based on mutanome-informed computational biology in patients with AML and MDS

Hypomethylating agents (HMAs) (azacitidine (aza), decitabine (dec)) and lenalidomide (len) are approved agents and used to treat patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML).

• Read more about A Prospective Clinical Trial to Predict Treatment Response Based on Mutanome-Informed Computational Biology in Patient with AML and MDS

Background: Hypomethylating agents (HMAs) (e.g., azacitidine (aza), decitabine (dec)) and lenalidomide (len) are approved agents and used in the treatment of patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML).

• Read more about A Genomic Signature Predicting Venetoclax Treatment Response in AML Identified By Protein Network Mapping and Validated By Ex Vivo Drug Sensitivity Testing: A beat AML Project Study

Background: Data from a small clinical trial of venetoclax in acute myeloid leukemia (AML) recently supported FDA breakthrough therapy designation for use in combination with hypomethylating agents in treatment-naïve patients who are ineligible for high-dose induction chemotherapy.